Philip J. Mease, MD, MACR
Swedish Medical Center/Providence St. Joseph Health
University of Washington School of Medicine
As a result of participation in this educational activity, participants should increase their ability to:
Summarize findings from recent clinical trials on biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA
Discuss latest evidence about targeted synthetic DMARDs for treatment of PsA
Consider the impact of the COVID-19 pandemic on PsA care
Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
- Planners (Forefront Collaborative): Christine Tebben and Marianna Shershneva, MD, PhD
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
Faculty Presenter: Philip J. Mease, MD, MACR
- Consultant: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB
- Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB
Faculty Presenter: Madelaine A. Feldman, MD, FACR
- Advisory Board: Bristol Myers Squibb, Gilead, Lilly, Merck, Pfizer, Samsung
The target audiences are rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Forefront Collaborative designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Content Review
The views and opinions expressed in this activity are those of the faculty and did not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.
Approved ACR Education Partner
This activity is included in the ACR’s Education Partner program. Independent reporting and the viewpoints expressed are those of Forefront Collaborative and its affiliates and do not represent the ACR.
This activity is provided by Forefront Collaborative.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.